文献速递炎症性肠病

二十碳五烯酸降低溃疡性结肠炎患者粪便钙卫蛋白水平并预防复发

Eicosapentaenoic Acid Reduces Fecal Levels of Calprotectin and Prevents Relapse in Patients With Ulcerative Colitis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2018-01-31

这项安慰剂对照试验纳入60例部分Mayo评分<2且粪便钙卫蛋白≥150 μg/g的溃疡性结肠炎患者,随机给予EPA-FFA 500 mg每日两次或安慰剂治疗6个月。EPA-FFA组63.3%达到粪便钙卫蛋白较基线下降100分的主要终点,高于安慰剂组的13.3%(OR 12.0,95%CI 3.12-46.24,P<.001),且无严重不良事件。

要点

  • EPA-FFA组19/30(63.3%)达到粪便钙卫蛋白下降100分,安慰剂组4/30(13.3%)(OR 12.0,P<.001)。
  • EPA-FFA组23/30(76.7%)维持临床缓解,安慰剂组15/30(50%)(OR 3.29,P=.035)。
  • 研究期间未观察到严重不良事件。

核心结论

  • 在60例溃疡性结肠炎患者的安慰剂对照试验中,给予EPA-FFA 6个月可降低粪便钙卫蛋白水平,且无严重不良事件。
  • 作者认为该药可能用于诱导和维持溃疡性结肠炎患者的无症状缓解。

研究设计与样本

  • 安慰剂对照试验,2014年6月至2016年5月纳入60例溃疡性结肠炎患者。
  • 入组条件为部分Mayo评分<2、粪便钙卫蛋白≥150 μg/g,且此前至少3个月维持稳定治疗。
  • 患者按1:1随机接受EPA-FFA 500 mg每日两次或安慰剂治疗6个月,基线时行结肠镜检查。

主要发现

  • 主要终点为6个月时粪便钙卫蛋白较基线下降100分,EPA-FFA组19/30(63.3%)达到 vs 安慰剂组4/30(13.3%)(OR 12.0,95%CI 3.12-46.24,P<.001)。
  • 次要终点为6个月时维持临床缓解,EPA-FFA组23/30(76.7%)达到 vs 安慰剂组15/30(50%)(OR 3.29,95%CI 1.08-9.95,P=.035)。
  • 未观察到严重不良事件。

临床怎么用

  • 作者认为EPA-FFA可能用于诱导和维持溃疡性结肠炎患者的无症状缓解。
  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: High fecal levels of calprotectin indicate mucosal inflammation and have been shown to predict relapse in patients with ulcerative colitis (UC). Eicosapentaenoic acid (EPA), the major component of n-3 fish oil, has anti-inflammatory properties in patients with chronic inflammatory disorders. We performed a placebo-controlled trial of patients with UC at risk of relapse to determine the ability of the free fatty acid form of EPA (EPA-FFA) to reduce intestinal inflammation, using fecal level of calprotectin as a marker. METHODS: From June 2014 to May 2016, 60 patients with UC with a partial Mayo score < 2 and fecal calprotectin ≥150 μg/g, in stable therapy for at least the 3 previous months, were randomly assigned to groups (1:1) given either EPA-FFA (500 mg, twice daily) or placebo for 6 months. A colonoscopy was performed at baseline. Clinical assessments and measurements of fecal calprotectin were made at baseline, at study months 3 and 6, or the time of clinical relapse. Patients with a relapse of UC underwent a second colonoscopy. The primary end point was a 100-point reduction in fecal levels of calprotectin at 6 months from the baseline value; the secondary end point was maintenance of clinical remission at 6 months. RESULTS: The primary end point was achieved by 19 of 30 patients (63.3%) in the EPA-FFA group vs 4 of 30 patients (13.3%) in the placebo group (odds ratio, 12.0; 95% CI, 3.12-46.24; P < .001). The secondary end point was achieved by 23 of 30 patients (76.7%) in the EPA-FFA group vs 15 of 30 (50%) patients in the placebo group (OR, 3.29; 95% CI, 1.08-9.95; P = .035). No serious adverse events were observed. CONCLUSIONS: In a placebo-controlled trial of 60 patients with UC, we found 6 months' administration of EPA-FFA to reduce fecal levels of calprotectin with no serious adverse events. This agent might be used to induce and maintain symptom-free remission in patients with UC. ClinicalTrials.gov number: NCT02179372.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Scaioli E, Sartini A, Bellanova M, et al. Eicosapentaenoic Acid Reduces Fecal Levels of Calprotectin and Prevents Relapse in Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2018. PMID: 29391271. doi:10.1016/j.cgh.2018.01.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。